nav arrow

CogWellin™ and Diabetes Mellitus

CogWellin™ targets the right patients at the right time.

Many years ago, the term type 3 diabetes was used to describe the metabolic similarities between Alzheimer’s disease and diabetes mellitus. In diabetes there is a great deal of inflammation shown through blood work. Both AD and DM are characterized by elevated insulin levels. I came upon an article written by a Dr. Ebstein in Germany in 1876.  He refers to using salicylic acid in a diabetic patient. As there were no blood tests for sugar, he tested the amount of sugar in the urine of his diabetic patients and noted a dramatic reduction in the urinary amount of sugar.  Fast forward to 1901, when a Dr. Harrison in England published a paper replicating the work of Ebstein in several of his diabetic patients.

In 1921, Banting and Best isolated insulin and that was the drug of choice for diabetics. Many chemicals have been made since then to lower blood sugar but none are naturally derived. They are foreign substances that the human body does not recognize as “normal” and a large number of both minor and life threatening side effects are reported.

The need for a natural, safe and time tested approach using salicylic acid seemed quite logical to a few scientists. In 2017, a paper was published by Goldfine and Shoelson from the Joslin Diabetes center which showed, similar to the work 116 years ago in Harrison’s paper, use of salicylic acid in the form of immediate release salsalate can lower blood sugar, lower hemoglobin A1C in diabetic patients already taking anti-diabetic agents.

Because of wide fluctuations in the blood levels of salicylate given to healthy volunteers and those with diabetes, it was logical to Dr. Joel Ross to use the long acting, provisionally patented CogWellin™ for those at risk for diabetes as well as for those with established diabetes. A study based on these principles can be undertaken as soon as the final formulation of an encapsulated form of once daily Salsalate is completed.